Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via…

Read More

Thirty Years of Lactobacillus rhamnosus GG: A Review.

Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41 Authors: Capurso L Abstract Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. Furthermore LGG is able to produces both a biofilm that can mechanically protect the mucosa, and different soluble factors beneficial to the gut by enhancing intestinal crypt survival, diminishing apoptosis…

Read More

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol. 2018 Nov 14;: Authors: Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) published guidelines on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) in August 2017 recommending use of reactive TDM to guide treatment changes in patients with active IBD who are being treated with anti-tumor necrosis factor (anti-TNF) agents or thiopurines. We sought to determine if changes in national clinical…

Read More

Financial Toxicity in Crohn’s Disease.

Financial Toxicity in Crohn’s Disease. J Clin Gastroenterol. 2018 Oct 24;: Authors: Voit A, Cross RK, Bellavance E, Bafford AC Abstract BACKGROUND: A patient-reported outcome measure called Comprehensive Score for Financial Toxicity (COST) was previously developed and validated in patients with cancer. GOALS: We sought to assess the financial toxicity associated with Crohn’s disease (CD) by administering the COST questionnaire to patients treated at a tertiary care center. STUDY: Forty-eight patients diagnosed with CD completed questionnaires, which included the COST quality of life instrument as well as questions with regard…

Read More

Narrow Band Imaging for Surveillance in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Narrow Band Imaging for Surveillance in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018 Aug 09;: Authors: Lv XH, Wang BL, Cao GW Abstract BACKGROUND: The role of narrow band imaging (NBI) for surveillance colonoscopy in patients with inflammatory bowel disease (IBD) is debatable. We aim to compare NBI versus other endoscopic techniques in surveillance of IBD basing on current evidences. METHODS: A systematic search of PubMed, Embase, and the Cochrane Library databases was conducted for relevant studies. To assess the detection efficacy, we estimated risk…

Read More

Hepatotoxicity of Inflammatory Bowel Disease Medications.

Hepatotoxicity of Inflammatory Bowel Disease Medications. J Clin Gastroenterol. 2018 Jul 20;: Authors: Shamberg L, Vaziri H Abstract Various medications used to treat inflammatory bowel diseases have been implicated to cause hepatotoxicity. These include sulfasalazine, 5-aminosalicylic acids, fluoroquinolones, metronidazole, thiopurines, methotrexate, anti-tumor necrosis factor agents, and alpha-4 integrin inhibitors. Various types of liver injury have been reported in association with these medications including hypersensitivity reaction, hepatocellular or cholestatic disease, nodular regenerative hyperplasia, liver fibrosis/cirrhosis, portal hypertension and autoimmune liver injury. The revised Roussel Uclaf Causality Assessment Method (RUCAM) provides a…

Read More

Probiotics in Pediatric Gastroenterology: Emerging Indications: Inflammatory Bowel Diseases.

Probiotics in Pediatric Gastroenterology: Emerging Indications: Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 Jul 20;: Authors: Scarpato E, Russo M, Staiano A Abstract Etiology of inflammatory bowel disease (IBD) is not yet completely understood, but it is hypothesized that a disruption of the immune tolerance to gut microbiota, due to several potential factors like an abnormal gut microbiota composition and activity, may lead to IBD occurrence. Manipulation of the intestinal microbiota is an attractive target for the management of IBD, and probiotics could be useful to influence the disease’s course.…

Read More

Oral and Otorhinolaryngological Findings in Adults Who Were Diagnosed With Pediatric Onset Crohn’s Disease: A Controlled Study.

Oral and Otorhinolaryngological Findings in Adults Who Were Diagnosed With Pediatric Onset Crohn’s Disease: A Controlled Study. J Clin Gastroenterol. 2018 Jun 16;: Authors: Haaramo A, Alapulli H, Aine L, Tuokkola J, Saarnisto U, Roine RP, Pitkäranta A, Kolho KL Abstract BACKGROUND: Up to 50% of pediatric patients with Crohn’s disease (CD) report oral manifestations, but less is known about their oral health when they become adults. GOALS: Our aim was to provide detailed descriptions of the presence of oral and otorhinolaryngological manifestations in patients with pediatric onset CD once…

Read More

Link Between Celiac Disease and Inflammatory Bowel Disease.

Related Articles Link Between Celiac Disease and Inflammatory Bowel Disease. J Clin Gastroenterol. 2018 May 14;: Authors: Shah A, Walker M, Burger D, Martin N, von Wulffen M, Koloski N, Jones M, Talley NJ, J Holtmann G Abstract GOAL: The aim of this analysis was to assess in patients with inflammatory bowel disease (IBD) the risk of celiac disease and in celiac disease patients the risk of IBD. BACKGROUND: Previous studies report a possible association between IBD and celiac disease; however, this link is controversial. STUDY: Using the search terms…

Read More
<< Go Back